PofoliaPofolia ile paylaşıldı

Asia Pacific Allergy· 2026Q2

Pumecitinib nazal spreyinin alerjik rinitli fare modelinde farmakolojik etkileri

Pharmacological effects of pumecitinib nasal spray in a mouse model of allergic rhinitis

Hui Zhang, Wei Hu, Ming Li, Li Zhu ve diğerleri

Kısa özet

Pumecitinib nazal spreyi (%0.1 ve %0.05), JAK1/2 kinazlarını inhibe ederek farelerde hapşırma, nazal inflamasyon ve IgE seviyeleri dahil alerjik rinit semptomlarını önemli ölçüde azaltmıştır.

Yapay zekâ ile başlık ve abstract'tan üretildi; tam metin okunmaz.

Ana noktalar

  • Pumecitinib, JAK1 ve JAK2 kinazlarını seçici olarak inhibe eder.
  • Pumecitinib nazal spreyi, sitokin kaynaklı STAT fosforilasyonunu baskılamıştır.
  • %0.1 pumecitinib nazal spreyi, alerjik rinitli bir fare modelinde hapşırma ve nazal inflamasyon belirteçlerini önemli ölçüde azaltmıştır.
  • Hem %0.1 hem de %0.05 pumecitinib nazal spreyi, epitel kalınlığını, eozinofil infiltrasyonunu ve OVA'ya özgü IgE seviyelerini düşürmüştür.

Yapay zekâ ile başlık ve abstract'tan üretildi; tam metin okunmaz.

Özet (abstract)

Background: Allergic rhinitis (AR) is an inflammation of the nasal mucosa primarily mediated by antigen-specific immunoglobulin E (IgE) and characterized predominantly by type 2 inflammation, in which the Janus kinase–signal transducer and activator of transcription (JAK-STAT) signaling pathway plays a critical role. Targeted inhibition of this pathway using small-molecule JAK inhibitor nasal sprays may represent a promising therapeutic strategy for AR. Objective: To evaluate the pharmacological profiles of pumecitinib (aka PG-011), a JAK inhibitor formulated as a nasal spray, for the treatment of AR in a mouse model. Methods: The inhibitory activity and selectivity of pumecitinib against JAK kinases were assessed in enzymatic assays. Its effects on cytokine-induced STAT phosphorylation (pSTAT) were evaluated in cellular assays. The pharmacological effects of pumecitinib nasal spray were investigated in an ovalbumin (OVA)-induced AR mouse model. Results: Pumecitinib was identified as a potent and selective inhibitor of JAK1 and JAK2 kinases relative to JAK3 and TYK2. It effectively suppressed pSTAT production induced by multiple cytokines, including interleukin (IL)-4, IL-31, and granulocyte-macrophage colony-stimulating factor. In the OVA-induced AR model, intranasal administration of 0.1% pumecitinib spray significantly reduced the frequency of sneezing episodes, as well as markedly attenuated nasal mucosal epithelial thickness, goblet cell hyperplasia, and eosinophil infiltration. The 0.05% concentration also produced significant reductions in epithelial thickness and eosinophil count. Both concentrations significantly lowered OVA-specific IgE levels in nasal lavage fluid. Conclusion: These findings demonstrate that pumecitinib nasal spray, through targeted inhibition of JAK1/2 kinases, exhibits pharmacological activity in a mouse model of AR, supporting its potential as a therapeutic candidate for further translational investigation in AR.

Yazarların özeti; kaynağından alınmıştır. Asia Pacific Allergy, 2026 · DOI ↗

ÇıkarımlarPremium
Makaleye SorÜcretsiz hesapla

Ücretsiz hesapla devam et

Makaleye Sor ile bu makaleye günde 3 soru ücretsiz; makaleyi kaydet, kaynakçasını al, ilgi alanına göre her gün yeni özetler. Çıkarımlar Premium.

Web'de ücretsiz devam et

Google ya da Apple hesabınla giriş; kart istemez. Bu makaleye geri dönersin.

Telefonda:

Alan: İmmünoloji ve Alerji

Immunology and AllergyMedicine